Lipidomic Profiling of Mastoid Bone and Tissue from Patients with Chronic Otomastoiditis

Farbod Fazlollahi1 Kessiri Kongmanas2 Nongnuj Tanphaichitr2 Jeffrey Suh3 Kym Faull1 Quinton Gopen3

1 Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, United States
2 Department of Biochemistry/Microbiology/Immunology, University of Ottawa, Ottawa, Ontario, Canada
3 Department of Otorhinolaryngology–Head and Neck Surgery, UCLA Health System, Los Angeles, California, United States

Address for correspondence Farbod Fazlollahi, BS, Department of Psychiatry and Biobehavioral Sciences, UCLA, 760 Westwood Plaza, CHS 68-146, Los Angeles, CA 90095, United States (e-mail: farbodfazlollahi@gmail.com).

Abstract

Introduction Chronic otomastoiditis causes pain, otorrhea, and hearing loss resulting from the growth of tissue within the normally hollow mastoid cavity.

Objectives In this report, we used a lipidomics approach to profile major mastoid bone and tissue lipids from patients with and without otomastoiditis.

Methods The bone dust created during mastoidectomy, as well as the mastoid tissue, was analyzed from seven patients. Bone dust was also collected and analyzed in an additional four otologic cases (parotidectomy requiring mastoidectomy). Samples were subjected to a modified Bligh/Dyer lipid extraction, then high-performance thin-layer chromatography (HPTLC), combined gas chromatography/electron impact-mass spectrometry (GC/EI-MS), and flow-injection/electrospray ionization-tandem mass spectrometry (FI/ESI-MSMS). Data were analyzed for identification and profiling of major lipid components.

Results HPTLC revealed the presence of various lipid classes, including phosphatidylcholines, cholesterol, and triacylglycerols. GC/EI-MS analysis revealed the presence of cholesterol and several fatty acids. FI/ESI-MSMS analysis revealed a host of phosphatidylcholines, phosphatidylethanolamines, and cholesteryl esters.

Conclusion We used a lipidomics approach to develop an efficient (both in time and tissue amount) methodology for analysis of these tissues, identify the most abundant and common lipid species, and create a base of knowledge from which more focused endeavors in biomarker discovery can emerge. In an effort toward improved patient categorization and individualized intervention, the ultimate goal of this work is to correlate these lipid molecules to disease state and progression. This is the first reported study of its kind on these tissues.

Keywords► mastoiditis
► lipid metabolism
► mass spectrometry
► flow injection analysis

Introduction

Chronic otomastoiditis refers to an inflammatory condition involving the middle ear and mastoid compartments. In the United States alone, chronic otomastoiditis is estimated to account for over 30 million physician visits each year with an annual cost of roughly 3 to 5 billion dollars, and it remains a common indication for antibiotic therapy and surgery.1
Interestingly, this pathology is also found in a significant proportion of indigenous children from the United States, Canada, Northern Europe, Australia, and New Zealand, the implication of which is obscure. Chronic otomastoiditis can result in hearing loss, vertigo, facial paralysis, sigmoid sinus thrombosis, meningitis, increased intracranial pressure, brain abscess, and in rare cases can even lead to death. In this condition, the normally air-filled middle ear and mastoid compartments become infiltrated and opacified by soft tissue–like material, which frequently requires surgical removal because resolution of symptoms is not achieved by antibiotic, anti-inflammatory, or other treatments.

When the surgically removed mastoid tissue is evaluated by histologic methods, chronic inflammation is almost always seen as demonstrated by an infiltration of polymorphonuclear cells and lymphocytes as well as a deposition of dense fibrotic tissue. Interestingly, standard swab and plate culture techniques rarely identify any associated pathogens. Several possibilities have been proposed to account for the production of this material, including infectious, autoimmune, neoplastic, and allergic processes. Despite the negative results with swab and plate techniques, an infectious etiology should not be excluded as there are plausible explanations as to why pathogens have evaded detection. These include the presence of biofilms, polysaccharide matrices created by bacteria that protect or shield them from the host response. Once enveloped within the biofilm, bacteria are difficult to detect by standard swab and plate techniques. The true relationship between mastoiditis and this material is still unknown. This continues to be a significant barrier toward clinical progress for treatment.

Lipids play crucial roles in cell, tissue, and organ physiology; not only do they provide an energy reservoir and serve as structural components of membranes, but they also act as signaling molecules and hormone precursors. Consequently, their steady-state concentrations are under tight homeostatic control, perturbation of which leads to disease and injury. Lipidomics aims to profile lipids such that the data sets can be used to compare control and disease states. Relating the lipidome to the proteome and the genome is an emerging field that provides an experimental platform with which complex biochemical systems can be related to genetic, developmental, and environmental influences; superimposed over these factors, the effect of disease states can be studied. With the ultimate goal of identifying lipid biomarkers of otomastoiditis, the first step is to identify the major lipid components of the involved tissues. In this report, we used high-performance thin-layer chromatography (HPTLC), combined gas chromatography (GC)/electron impact (EI)-mass spectrometry (MS), and flow-injection (FI)/electrospray ionization (ESI)-tandem mass spectrometry (MSMS) to qualitatively identify the major lipid classes in the mastoid tissue and mastoid compartment bone dust (BD). A necessary first step toward elucidating the composition and mechanisms behind its production, this information is fundamental to further identification of clinical biomarkers for otomastoiditis, and subsequently efficient patient diagnosis and treatment.

Methods

Solvents

Chloroform, methanol, and formic acid (FA) were purchased from Fisher Scientific (San Jose, California, United States). Triethylamine (TEA), butylated hydroxytoluene (BHT), and ammonium acetate (AA) were purchased from Sigma Aldrich (St. Louis, Missouri, United States).

Patients Recruitment and Biological Sample Collection

With approval from and strict adherence to the Medical Institutional Review Board guidelines and regulations, samples were collected after written consent was obtained before surgery from patients with and without chronic otomastoiditis. Recruited patients included those who showed clinical symptoms consistent with the diagnosis such as otorrhea, hearing loss, and otalgia. Furthermore, these patients showed the presence of pathologic mastoid tissue, as revealed by a computed tomography scan. Four additional cases of patients undergoing mastoidectomy during exposure of the facial nerve for parotid tumors were recruited to participate in this study and provide samples for the BD group.

Sample Collection

In the operating room, mastoid tissue was excised into sterile plastic specimen cups, and BD was collected after drilling through the mastoid bone. Specimens were stored on ice for transportation to the laboratory, where they were then transferred to 1.5-ml microcentrifuge tubes, to which 500 µL of ice-cold deionized water was added. Tubes were mixed briefly to wash and remove excess blood, then centrifuged at low speed (2,000g). The supernatant was discarded and the process was repeated twice. Samples were then stored at −80°C.

Sample Extraction

To minimize hydrolysis or degradation, the workup was done on ice as swiftly as possible. Samples were thawed at room temperature and then placed on ice. A small piece of chronic otomastoiditis tissue (COT) from each patient was placed on an ethanol-cleaned watch glass, also on ice, and diced (roughly 500-µm² pieces) with a no. 10 scalpel (sterilized for 30 minutes in ethanol) to aid in homogenization. The BD was already amenable to homogenization and extraction, so this consideration was unnecessary. To prevent oxidation, BHT (final concentration 300 μM) was added to all solutions and solvents used throughout the lipid extraction procedures. Roughly 1 mg of tissue from each patient’s COT was pooled into a glass test tube and roughly 20 mg of BD from each patient were pooled into another tube, and 1 mL of deionized water containing BHT (dH2O + BHT) was added to both. The pooled samples were then homogenized while on ice, either with an ultra-sonic cell disrupter (Branson, three 15-second bursts with a 5-minute interval in between) or a Brinkman Polytron Homogenizer (30 seconds).

After settling, 10 µL aliquots of the supernatants were diluted 1:100 in dH2O + BHT and the optical density
determined at 417 nm against a water blank (Beckman DU 640B spectrophotometer). A 60-µL aliquot of freshly drawn human blood was diluted in 1 mL dH2O + BHT, sonicated as described above, and the OD417nm determined. From a comparison of the absorption intensities, control human blood samples were then prepared at an appropriate dilution in dH2O + BHT to match the hemoglobin, and theoretically, the blood content of each tissue sample.

The remainder of each homogenized suspension and the matched human blood samples (990 µL each) were then subjected to a modified Bligh-Dyer lipid extraction. In an aqueous suspension, 1,237.5 µL of chloroform containing 300 µM BHT (CHCl3 + BHT) and 2,475 µL methanol containing 300 µM BHT (MeOH + BHT) were added to each sample to achieve a chloroform:methanol:water ratio of 1:2:0.8, v/v/v. The samples were mixed thoroughly again, centrifuged (2,000g for 3 minutes), and the chloroform (bottom) phase was transferred with a glass syringe to 15-mL glass capped test tubes. The extraction was repeated once using a volume of CHCl3 + BHT identical to that removed in the previous step. The pooled chloroform phases were dried under a gentle stream of dry nitrogen gas, capped, and stored at −20°C.

**High-Performance Thin-Layer Chromatography**

HPTLC was performed to elucidate the complexity of the tissue samples and broadly identify major lipid classes. Each sample was redissolved in 100 µL of chloroform, from which a 5-µL aliquot was loaded as an 8-cm band onto a longitudinally prescored HPTLC plate and developed as described above. A narrow strip of this plate (5%) was detached (along the score) and stained with orcinol as described above. Based on the orcinol staining pattern the unstained part was divided into four zones (zone 1, relative to front (Rf) 0.0 to 0.24; zone 2 Rf 0.24 to 0.47; zone 3 Rf 0.47 to 0.71; zone 4 Rf 0.71 to 1.0), and the silica from each was scraped into a clean glass tube (one zone/tube). The derivatized samples were treated with chloroform/methanol (1 mL, 1:1, v/v), and after centrifugation (2,000g, 5 minutes) the supernatants were collected into a new glass tube and the silica pellet was re-extracted once. The pooled supernatants were subjected to a Bligh-Dyer extraction by the addition of water (0.9 mL), the phases separated by centrifugation (2,000g, 5 minutes) and the chloroform phases were removed to clean glass vials. The Bligh-Dyer extraction was repeated once and the pooled chloroform phases were dried under a stream of nitrogen gas, resulting in four HPTLC fractions per sample. The dried samples were stored at −20°C.

**Gas Chromatography/Mass Spectrometry of the High-Performance Thin-Layer Chromatography Zones**

Each lipid fraction extracted from the HPTLC plate was redissolved in chloroform:methanol (500 µL, 1:1). Fifty microliters of each sample were transferred to glass conical GC injector vials and dried under a nitrogen stream. Each sample was then treated with 50 µL N.O-bis(trimethylsilyl)trifluoroacetamide containing 10% (v/v) trimethylchlorosilane and incubated (60°C, 60 minute) to convert all carboxyl, amino, and hydroxyl functional groups to their corresponding trimethylsilyl derivatives. The derivatized samples were then placed in an autosampler (Agilent 7683 series, Foster City, California, United States) from which an aliquot of each (1 µL, equivalent of 0.2% of the contents of the HPTLC fraction) was injected onto a bonded-phase nonpolar fused silica capillary column (Phenomenex ZB-5, phenyl/dimethylpolysiloxane 5/95, 60 m × 0.25 mm, 0.10-µm film thickness, Phenomenex, Torrance, California, United States; injector port 250°C) and eluted (constant flow, 1 mL/min) with ultra-high-purity helium (Agilent 6890A GC system) over a 63-minute temperature ramp (min/°C: 0/50, 3/50, 53/300, 63/300). The end of the column (GC/MS transfer line at 250°C) was directly inserted into the EI source (180°C, 70 eV) of a time-of-flight mass spectrometer (Waters GCT, calibrated with perfluorotributylamine immediately prior to the analysis of each batch of samples) scanning from m/z 40 to 650 (0.9 s/scan at a resolution [full width at half maximum] of 7,000, lock-mass from column bleed at 207.0329 C5H15Si3O3) with a 15-minute solvent delay. Data were collected with instrument manufacturer-supplied software (MassLynx version 4.1, Waters Corporation, Milford, MA). Each sample was individually prepared and run in duplicate.

Identification was based on comparison of spectra averaged over the width of the GC peaks within the total ion chromatogram, with background subtraction, to the National Institute of Standards and Technology (NIST) 2008 Mass Spectral Library (version 2.0f). These were based on NIST match factors of at least 750, indicating strong concordance between the unknowns and the library spectra, and acceptable visual concordance between the unknown and library spectra.

**Electrospray Ionization/Tandem Mass Spectrometry**

To screen for the major lipid classes on the basis of tandem mass spectra, identical lipid extracts were prepared as described above and dissolved in chloroform:methanol (500 µL, 1:1). To provide the appropriate milieu for effective
ionization, a 50-μL aliquot of each stock solution was diluted 1:5 (v/v) in chloroform:methanol:formic acid (200 μL, 50:50:0.1, v/v/v). Another 50 μL of each stock was diluted similarly in chloroform:methanol:triethylamine (200 μL, 50:50:0.1, v/v/v), and a third 50-μL aliquot was diluted similarly in chloroform:methanol:ammonium acetate (200 μL, 50:50:10 mM, v/v/v). Ten microliters of each of these dilutions, from each sample, were analyzed on an Agilent 6460 triple quadrupole mass spectrometer by flow injection into an Agilent Jet Stream ion source (gas temperature 300°C, gas flow 6 L/min, nebulizer pressure 45 psi, sheath gas temperature 50°C, sheath gas flow rate 10 L/min, capillary voltage 4,500 V, nozzle voltage 2,000 V) with chloroform: methanol (50:50) as the running solvent (100%, 0.050 mL/min). Data were collected with instrument manufacturer-supplied software (Agilent Mass Hunter version B.05.00).

Using published methods as a guide,12–21 optimal conditions for precursor, product, and neutral loss ion scans for the PtdCho/CerPCho, cholesteryl esters (CE), and sulfated lipids (S) were developed in-house using authentic standards (►Table 1). Optimization for each compound class was performed with solutions prepared in chloroform:methanol (50:50, v/v), 1 pmol/μL using 10-μL injections, containing either 10 mM AA (CE), 0.1% TEA (phosphatidyl serine [PtdSer], phosphatidyl inositol [PtdIns], and S), or 0.1% FA (PtdCho/CerPCho and phosphatidyl ethanolamine [PtdEtn]).12 The standards utilized for this purpose were: PtdCho, dihexanoyl phosphatidylcholine and 1-heptadecanoyl-1-lyso-phosphatidylcholine (Sigma Aldrich); PtdIns, L-α-phosphatidilylnositol sodium salt from Glycine max (soybean; Sigma Aldrich); PtdSer, 3-sn-phosphatidyl-L-serine sodium salt from bovine brain (Sigma Aldrich); Cer, ceramide from bovine spinal cord (Sigma Aldrich); PtdEtn, 3-sn-phosphatidylethanolamine from bovine brain (Sigma Aldrich). Instrument parameters (collision energy, fragmentor, and cell accelerator voltage) were manually tuned with repeat injections until maximal signal intensity for precursors ions were obtained in each scan modality. Limits of detection for these compounds were then determined by preparing serial dilutions of the standard solutions and running them at the aforementioned optimized conditions until the dilution at which a signal 3 times as intense as background was determined. Optimized instrument parameters and limits of detection for CE and S were previously determined on this instrument via similar means.22–24

Results

High-Performance Thin-Layer Chromatography Profiles
HPTLC was used to estimate the magnitude of blood contamination in the extracts. The OD417nm provided a convenient method for measuring hemoglobin, and therefore blood that inevitably comprises a portion of each sample. The contribution of blood to the lipid profiles of the tissue samples was insignificant (►Fig. 1). Co-spotted matched blood control samples for each tissue sample revealed relatively minor bands with the exception of C and possibly TAG, although the tissue samples were vastly stronger for these bands as well.

HPTLC was also used to gauge the complexity of the lipid profile in the samples and to screen for possible major differences between samples. Visual inspection of the plates revealed multiple bands in the region of PtdCho, CerPCho, bands in the region of CerLac, relatively minor bands between CerLac and C, and strong bands at the Rf of C and TAG (►Fig. 1). The results suggested that the samples were not sufficiently complex to warrant prefractionation ahead of tandem MS.

Gas Chromatography/Electron Impact-Mass Spectrometry Profiles of High-Performance Thin-Layer Chromatography Zones
The total ion chromatograms revealed a peak for C in zone 4 extracts from each of the sample groups (►Fig. 2), which was overloaded in the COT sample, and on-scale for the BD sample. In addition, less intense peaks were identified in both zone 4 extracts for palmitic, oleic, and stearic acids. Glycerol and

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Scan modalities for tandem mass spectrometric screens of major lipid classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid class</td>
<td>Dilution used</td>
</tr>
<tr>
<td>PtdCho/CerPCho</td>
<td>FA</td>
</tr>
<tr>
<td>PtdSer</td>
<td>TEA</td>
</tr>
<tr>
<td>PtdEtn</td>
<td>FA</td>
</tr>
<tr>
<td>PtdIns</td>
<td>TEA</td>
</tr>
<tr>
<td>Cer</td>
<td>FA</td>
</tr>
<tr>
<td>CE</td>
<td>AA</td>
</tr>
<tr>
<td>S</td>
<td>TEA</td>
</tr>
</tbody>
</table>

Abbreviations: AA, ammonium acetate; CE, cholesteryl esters; Cer, ceramide; CerPCho, sphingomyelin; FA, formic acid; LOD, limit of detection; PtdCho, phosphatidyl choline; PtdSer, phosphatidyl serine; PtdEtn, phosphatidyl ethanolamine; PtdIns, phosphatidyl inositol; S, sulfated lipids; TEA, triethyl ammonia.

Notes: LOD for CE not found due to high background at low concentrations. The LOD was determined from serial dilutions of standards prepared in-house, and the assigned value was the amount injected that gave a signal ~3 times more intense than background.

International Archives of Otorhinolaryngology Vol. 19 No. 2/2015
Flow-Injection/Electrospray Ionization-Tandem Mass Spectrometry Profiles

The MSMS approach to identify the components of the major lipid classes using flow injection with appropriately selected scan modalities (–Table 1) proved to be a fast and efficient screen. Using the redissolved Bligh/Dyer extracts, there was no evidence of ion suppression as learned from repeat injections of 10-fold concentrated samples from which there was the expected increase in signal intensity. The lack of ion suppression observed during flow injection validated the decision to forgo chromatography. Consequently, the analyses were both faster and shorter, adding to the efficiency of this screening method. The criteria for selection of significant ions from these spectra were that the same signal must be present in repeat injections from a given sample, and the peak intensity must be at least fivefold larger than the local baseline. Such stringent criteria were used to restrict this report to the most abundant species and keep the number of assigned peaks to a manageable level. The estimated limits of detection (LOD) for the different lipid classes varied from 200 and 450 fmol, to 5, 40, 50, and 100 pmol injected from S, PC/SM, PE, PS, PI, and C, respectively (–Table 1). These injected LODs were determined by injection of serial dilutions of the authentic standards as discussed above, and equate to tissue LODs between 125 fmol/mg (S) and 62.5 pmol/mg (Cer). Ion assignments in the collected spectra were made as protonated (MH⁺) and ammoniated (M + NH4⁺) molecules when FA and AA solvents were used, respectively.

The complexity of the spectra varied for the different classes, and representative MSMS spectra for the majorly present lipid classes (–Fig. 3) show the most abundant species in each. –Tables 2, 3, and 4 show precursor ions for four major lipid classes identified (PtdCho, PtdEtn, Cer, and CE, respectively) and the identity of the most intense ion from each sample. Signals for PtdIns, PtdSer, and S were not detected in any sample.

The parents of m/z 184 positive ion scan modality, used to screen for choline-containing lipids, rely on the facile production of the C5H15PO4N⁺ fragment ion produced during collisionally activated dissociation (CAD) from all PtdChos by cleavage of the moiety attached to the sn3 position of the glycerol backbone. Even with stringent selection criteria, in FA, this scan modality revealed a complex array of signals in the COT sample with more than 20 species present (–Fig. 3, –Table 2, even-numbered m/z values). However, the same scan and selection criteria in FA solvent revealed only two signals in the BD sample. The pair of ions at m/z 758 and 760, presumably differing by a single double bond, dominated both profiles and are assigned as 34a:2 and 34a:1 diacyl phosphatidylcholine, respectively. When identical samples were diluted in AA solvent, the profile from COT was even more complex, and astonishingly the profile from BD was equally complex with 24 and 20 assigned signals (even-numbered m/z values), respectively. Sprinkled among the even m/z signals are a small number of odd mass assignments.

The neutral loss of 141 Da positive ion scan mode was used to profile PtdEtns. This was based on the facile loss of the C2H8O4NP molecule from the protonated PtdEtn molecular ions during CAD. COT revealed up to 8 and 14 different species in FA- and AA-containing solvent, respectively (–Fig. 3, –Table 3). BD revealed two and nine different species in the same solvents, respectively. The most abundant phosphate were also identified; however, their presence in all four zones of both COT and BD relegated them to the status of contaminants. Based on an estimated limit of detection of 1 ng injected, the inferred content of any free fatty acids in the samples must be greater than ~5.5 ng per mg of COT and 260 pg per mg of BD.
species in all samples were the pair of ions at m/z 768 and 766, corresponding to 38a:4 and 38a:5 diacyl phosphatidyl-
ethanolamine, respectively. The profiles also revealed a few odd mass assignments.

The parents of m/z 369 positive ion scan modality in AA-containing solvent was used to profile CEs. This scan modality was based on the facile fragmentation of the all CE (M + NH4)⁺ parents yielding an intense ion for the cholesterol-containing fragment (C27H49) during CAD. COT and BD revealed 22 and 2 different molecular species, respectively, of which the signal at m/z 666 corresponding to the linoleate ester was most intense in both (►Fig. 3, ►Table 4).

The scan modality for PtdSer, the neutral loss of 87 Da in the negative ion mode in TEA solvent, was based on the loss of the serine functionality (C3H5NO2) from the (M-H)⁻ parent ion common to these compounds. The scan modality for Cer, parents of m/z 264, was based on the formation of a common positive rearrangement CAD fragment ion C18H34N displayed by these compounds in FA solvent. The scan modality for S was based on extensive in-house experience with these lipids in which the common negative fragment ion at m/z 97 (HSO4⁻/) forms the basis of the scan in the negative ion mode in TEA solvent.

Discussion

There is no one technique capable of conveniently displaying all lipids in a sample. As such, we have used a combination of
Fig. 3  Representative tandem mass spectrometry spectra of the majorly present lipid classes in mastoid tissue. (a) Precursor ion scan of m/z 369.4 shows cholesteryl esters and similar compounds. (b) Precursor ion scan of m/z 184 of samples shows phosphatidylcholines, sphingomyelins, and similar compounds. (c) Neutral loss scan of m/z 141 of samples shows phosphatidylethanolamines and similar compounds. (d) Precursor ion scan of m/z 264.1 shows ceramides and similar compounds. Compounds not shown here were present below the limit of detection.
HPTLC, GC/EI-MS, and FI/ESI-MSMS to probe the lipidome of these pathologic tissues. The different techniques provide complementary and partially overlapping profiles. To our knowledge, this is the first study of its kind to evaluate the lipid characteristics of mastoid bone and tissue, and it is a vital first step toward elucidation of putative biomarkers for otomastoiditis. The HPTLC profiles of Bligh-Dyer extracted samples provide convenient visualization of the major lipid components in one display, with the single major limitation of an LOD of \( \frac{C_{24}}{0.5} \) µg/compound (1 nmol with a molecular weight of 500). HPTLC is therefore a convenient way to gauge the complexity of any sample, and is particularly useful in this case where there is no precedence for analysis of middle ear bone and tissues. In contrast, MS has unrivalled sensitivity and specificity with the single major limitation being the lack of a scan modality that can be applied to all compounds. Because this work was not sample limited, we have used a combination of HPTLC and MS to provide a global qualitative analysis of the lipid components of bone and tissue from the two patient classes.

Inclusion of a blood control for each tissue type on the HPTLC chromatogram showed a relatively sparse banding pattern, indicating an insignificant contribution of blood to the tissue extracts. A variable blood contamination is unavoidable when working with any tissue and bone samples excised from living patients.

### Table 2

Tabulation of the major ions evident in the precursor of m/z 184 scan modality, characteristic of phosphatidylcholine-containing species

<table>
<thead>
<tr>
<th>Tissue type</th>
<th>Ion-pair reagent</th>
<th>Ions*</th>
<th>Identification of most intense species</th>
</tr>
</thead>
<tbody>
<tr>
<td>COT</td>
<td>FA</td>
<td>496.4, 454.4, 703.5, 720.3, 732.3, 734.6, 735.7, 746.7, 758.5, 782.5, 784.6, 786.6, 794.4, 796.4, 808.6, 810.5, 834.4, 836.8</td>
<td>34a:1 diacyl phosphatidylcholine</td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>520.4, 522.4, 544.1, 675.1, 703.6, 717.8, 720.5, 732.7, 734.5, 744.8, 746.8, 748.5, 758.6, 760.6, 768.2, 782.6, 784.6, 796.6, 796.3, 806.4, 808.5, 810.6, 812.7, 832.6, 834.4, 836.5</td>
<td>34e:2 alkyl ether phosphatidylcholine</td>
</tr>
<tr>
<td>BD</td>
<td>FA</td>
<td>703.6, 758.4, 760.6</td>
<td>34a:2 diacyl phosphatidylcholine</td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>496.6, 520.4, 544.1, 675.1, 676.3, 689.6, 703.5, 724.4, 734.3, 744.1, 746.6, 748.3, 758.5, 760.5, 768.3, 782.5, 784.5, 786.3, 794.2, 799.7, 802.5, 806.4, 808, 810.4, 813.8</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Abbreviations: AA, ammonium acetate; BD, bone dust; COT, chronic otomastoiditis tissue; FA, formic acid.

Notes: This listing includes only the signals that were more intense than fivefold above baseline. Close inspection of the spectra reveals many less intense signals. The LOD was determined from serial dilutions of standards prepared in-house, and the assigned value was the amount injected that gave a signal ~3 times more intense than background.

*Most intense shown in bold.

### Table 3

Tabulation of the major ions evident in the neutral loss of 141-Da scan modality, characteristic of phosphatidylethanolamine-containing species

<table>
<thead>
<tr>
<th>Tissue type</th>
<th>Ion-pair reagent</th>
<th>Ions (most intense in bold font)</th>
<th>Identification of most intense species</th>
</tr>
</thead>
<tbody>
<tr>
<td>COT</td>
<td>FA</td>
<td>740.5, 742.5, 744.5, 746.5, 747.6, 764.5, 766.2, 768.5, 769.5, 770.6</td>
<td>38a:4 diacyl phosphatidylethanolamine</td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>716.4, 718.5, 740.5, 742.4, 744.5, 746.5, 754.5, 764.5, 766.4, 768.4, 769.5, 770.5, 792.5, 793.5, 794.5, 796.6</td>
<td>38a:4 diacyl phosphatidylethanolamine</td>
</tr>
<tr>
<td>BD</td>
<td>FA</td>
<td>766.5, 768.2</td>
<td>38a:5 diacyl phosphatidylethanolamine</td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>716.5, 718.5, 740.5, 742.6, 744.5, 764.5, 766.5, 768.4, 770.6</td>
<td>38a:4 diacyl phosphatidylethanolamine</td>
</tr>
</tbody>
</table>

Abbreviations: AA, ammonium acetate; BD, bone dust; COT, chronic otomastoiditis tissue; FA, formic acid.

Notes: This listing includes only the signals that were more intense than fivefold above baseline. Close inspection of the spectra reveals many less intense signals. The LOD was determined from serial dilutions of standards prepared in-house, and the assigned value was the amount injected that gave a signal ~3 times more intense than background.

*Most intense shown in bold.

*Odd-numbered m/z values.
regions. By visual inspection, and considering that the amount of BD used in these analyses was 20 times by wet weight that of the tissue, BD had a lower lipid concentration across the chromatogram as compared with COT; however, there was no gross difference between the chromatograms, other than the difference in opacity attributable to the relatively higher richness of lipid content in tissue. This means the major lipid components of these tissues are similar in type, but not in amount. It is unlikely that a small subpopulation of each sample pool could dominate the chromatogram because each sample in each pool is present in roughly equal quantities.

The GC/EI-MS lipidomic profiling of the trimethylsilyl-oxime derivatives of Bligh-Dyer extracts of COT and BD samples revealed a similar lipid complexity; however, BD was comparatively deficient in C. This phenomenon can likely be attributed to the relatively higher concentration of C inherent to tissue as compared with bone. The low abundance of free fatty acids is of note. These compounds are important components of intermediary metabolism. Their low concentrations could be indicative of a possible acellular nature of the samples.

The MSMS work provided a more sensitive and directed profiling of the lipid content of these samples. The most abundant lipids detected were members of the PtdEtn, PtdCho, and CE classes. PtdChos are the principal phospholipids in human cell membranes and are a pulmonary surfactant. PtdEtns are the principal phospholipids; therefore, their relative abundance may be indicative of a bacterial presence despite the failure of the swab and plate culture experiments previously referred to. Application of the nitrogen rule to putative PtdEtns previously would mean the assigned parent ions would be even when protonated (in FA solvent) and odd when ammoniated (only in AA solvent). The presence of the same ion in both FA and AA solvents implies that at least some of the ions detected in AA solvent are protonated. The few odd-value assignments are not likely to be PtdEtns.

Interestingly, CEs are among the major contributors to local lipidome in mastoid tissue and bone and are present in much greater abundance and variety in mastoid tissue. As shown in Table 4, both cholesteryl arachidonate and cholesteryl linoleate are present in mastoid tissue, but only cholesteryl linoleate is present both tissue types studied here. These findings could be potentially significant. According to Do et al, cholesteryl arachidonate and cholesteryl linoleate show microbicidal effects in vitro, including against *Pseudomonas aeruginosa*, a common human pathogen whose infection causes generalized inflammation and potentially sepsis. The differential presence of these antimicrobial lipids across the different tissue types analyzed and the significance of the variety of these lipids in the idiopathic mastoid tissue will be a topic of future study.

PtdSer, PtdIns, Cer, and S were present below the limit of detection in these samples (40 pmol, 50 pmol, 100 pmol, and 200 pmol, respectively, injected; Table 1). This is an unexpected result as PtdIns and PtdSer are relatively common cellular membrane structural phospholipids and sulfated lipids play roles in cell-surface signaling. The significance of this finding is obscure at the moment. This is not to say that these lipid classes do not exist in mastoid tissue and/or mastoid bone, but rather their respective concentrations in these tissues is low, and a more sensitive targeted assay for them is required. The latter will be explored in future work.

**Conclusions**

These results represent a first step to characterize the lipid profile of patients with otomastoiditis and to identify

<p>| Table 4 Tabulation of the major ions evident in the precursor of m/z 369 scan modality, characteristic of cholesteryl esters |
|------|-----------------------|---------------------------------------------|</p>
<table>
<thead>
<tr>
<th>Tissue type</th>
<th>Ion-pair reagent</th>
<th>Ions (most intense in bold font)</th>
<th>Name of most intense species</th>
</tr>
</thead>
<tbody>
<tr>
<td>COT</td>
<td>AA</td>
<td>404.3, 614.6, 640.1, 642.6, 664.6, 666.6, 668.6, 670.6, 690.5, 692.5, 694.7, 696.5, 714.8, 716.5, 718.5, 720.4, 722.7, 744.6, 746.5, 748.8, 750.6, 778.5</td>
<td>Cholesteryl linoleate</td>
</tr>
<tr>
<td>BD</td>
<td>AA</td>
<td>404.2, 666.6</td>
<td>Cholesteryl linoleate</td>
</tr>
</tbody>
</table>

Abbreviations: AA, ammonium acetate; BD, bone dust; COT, Chronic otomastoiditis tissue.
Notes: This listing includes only the signals that were more intense than 5-fold above baseline. Close inspection of the spectra reveals many less intense signals. The limit of detection for this scan modality is listed in Table 1.
potential biomarkers of the disease. As there is a dearth of literature on lipidomic profiling in bone, this report sought to develop an efficient and catholic analytical method for these tissues. Given the large and diverse role of lipids in tissue structure and the regulation of local homeostasis, the lipidome of the mastoid compartment is a logical place to begin looking for candidate biomarkers. The techniques developed in this study will be exploited in further analyses of individual patient samples in the search for relative abundance of these major species as well as a broader global lipidome comparison.

References